Q-omics provides the consensus-scored WBP2NL profile across patient tissues and cancer cell-line models. WBP2NL expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, WBP2NL is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, WBP2NL RNA expression shows 18,901 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, THCA, and UVM as cancer lineages where WBP2NL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WBP2NL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WBP2NL survival associations across molecular data types. WBP2NL RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WBP2NL RNA expression–survival associations across cancer types. High WBP2NL expression shows unfavorable associations in LIHC and ACC, but favorable associations in LUAD, BLCA, PAAD and CESC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for WBP2NL RNA expression.
This table summarizes WBP2NL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for WBP2NL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WBP2NL shows lower tumor expression in THCA, KIRC and LUSC and higher tumor expression in LIHC, HNSC and CHOL. The THCA box plot shows higher WBP2NL RNA expression in normal versus tumor tissue (log2 FC = −0.411, t-test p < 0.001).
This table shows molecular features associated with WBP2NL in patient tissues and cancer cell lines. In patient samples, WBP2NL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, WBP2NL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and OVARY.
